Stay updated with breaking news from Tyme Technologies. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Tyme Technologies, Inc. (NASDAQ:TYME – Get Rating) insider Steve Hoffman sold 78,125 shares of the firm’s stock in a transaction that occurred on Monday, March 28th. The stock was sold at an average price of $0.34, for a total value of $26,562.50. The transaction was disclosed in a document filed with the SEC, which can […]
BEDMINSTER, N.J., March 29, 2022 -- TYME Technologies, Inc. , an emerging biotechnology company developing cancer metabolism-based therapies , today announced that its Board of Directors has... | March 29, 2022
Kercheville Advisors LLC trimmed its holdings in shares of Tyme Technologies, Inc. (NASDAQ:TYME – Get Rating) by 61.0% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 271,020 shares of the company’s stock after selling 423,450 shares during the quarter. Kercheville […]
-- Preclinical results from Georgetown University support that SM-88 is potentially a novel anti-cancer agent in drug resistant estrogen receptor positive...
EGRX earnings call for the period ending December 31, 2021.